Today: 29 June 2026
Westpac share price jumps 1.5% after “Book a Banker” launch — what to watch next
24 February 2026
1 min read

Westpac share price jumps 1.5% after “Book a Banker” launch — what to watch next

Sydney, Feb 24, 2026, 16:56 AEDT — Market closed.

  • Westpac finished the session 1.5% higher at A$42.65, just shy of its recent peak.
  • Banks held the line as the ASX 200 closed unchanged.
  • Next up for investors: Westpac’s interim results and dividend decision, slated for May 5.

Westpac Banking Corp (WBC.AX) closed Tuesday at A$42.65, up 1.5% or A$0.61 on the day. Shares changed hands between A$41.79 and A$42.65, with approximately 5.6 million traded.

The S&P/ASX 200 index finished just 0.04% lower, after slipping under 9,000 points earlier—hardly any change by the close, though that brief dip underscored how quickly sentiment can shift.

Westpac took the opportunity to lean into home-loan sales, introducing a “Book a Banker” tool that allows customers to schedule a lender appointment however they want—by phone, video, in the branch, or even somewhere else. “We know our customers are juggling work, family and everything in between, so the tool was designed to fit around busy lives,” Westpac Managing Director of Mortgages James Hutton said in a statement. Westpac

It’s relevant, given mortgage competition has turned fierce — boosting conversion and holding onto customers are now the simplest ways to eke out growth. Westpac earlier this month announced a 0.25 percentage point hike in variable home loan rates after the Reserve Bank of Australia’s cash rate move, a reminder of how sharply pricing shifts can trigger renewed attention on customer churn.

The move comes as investors have already been bidding up bank stocks on the back of resilient earnings. But Macquarie and Morgan Stanley analysts flagged in Market Index that pricey valuations now mean little margin for disappointment—despite a reporting season that saw most of the majors top forecasts.

Westpac’s latest figures capture both sides of the story. The Feb. 13 quarterly update showed net profit before notable items hitting A$1.9 billion. Net interest margin (NIM) dropped again, landing at 1.94%, as competition ate into returns; “core” NIM slipped three basis points, coming in at 1.79%. The bank’s common equity tier 1 (CET1) ratio, a key capital strength metric, was reported at 12.3%. Westpac

Shares in Westpac remain near their recent highs. Investing.com lists the 52-week range topping out at A$43.05.

There’s also a bullish scenario in play. Earlier this month, Reuters cited Westpac, which pointed to steady credit demand staying intact despite ongoing margin pressure—a balance that could swing fast if either funding costs tick up or loan growth loses steam.

Traders head into the next session eyeing offshore signals, following a turbulent stretch in global markets as U.S. tariff questions and shifting sentiment in AI-linked tech names begin to spill over into wider risk appetite.

Westpac’s next key event lands on May 5, with interim results and its interim dividend announcement on deck; its half-year wraps up March 31.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Guardant Health (GH) Stock Valuation Insights After 193% One-Year Gain
    June 28, 2026, 6:40 PM EDT. Guardant Health (GH) shares have surged 193.4% over the past year to around $149, raising questions about potential future gains. Despite strong price momentum, a Discounted Cash Flow (DCF) analysis estimates an intrinsic value near $159.10 per share, indicating the stock trades at a modest 6.2% discount. However, the company currently posts negative free cash flow ($232.49 million last twelve months) with projections to turn positive by 2030, reflecting ongoing challenges. Guardant Health scores just 1 out of 6 on valuation metrics, signaling caution for investors. The Price-to-Sales ratio is considered more relevant due to inconsistent profitability. Overall, GH appears fairly valued but market sentiment and fundamentals should be closely monitored for changes.

Latest articles

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

29 June 2026
Kroger (NYSE:KR) faces scrutiny after a USDA alert flagged mislabeled Private Selection Honey Dijon chicken in nine states, but with no confirmed adverse reactions and the product already off shelves, the stock closed Friday at $57.73, down 5 cents; any expansion of affected lots or confirmed cases could alter risk for investors.
Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod
Previous Story

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Apple stock price climbs as Houston Mac mini shift and China vote put tariffs in focus
Next Story

Apple stock price climbs as Houston Mac mini shift and China vote put tariffs in focus

Go toTop